Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges (Q37780220)

23 August 2017

1 reference

title

Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges (English)

1 reference

23 August 2017

author name string

Johannes Carl Christoph Lenz

series ordinal

1

1 reference

23 August 2017

Jürgen Kurt Rockstroh

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1139-1150

1 reference

CD4+ count-guided interruption of antiretroviral treatment

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Structure of a V3-containing HIV-1 gp120 core

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

The antigenic structure of the HIV gp120 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Structural and molecular interactions of CCR5 inhibitors with CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Biology of CCR5 and its role in HIV infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Drug interactions with new and investigational antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.510833

10.1517/17425255.2010.510833

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference